MX2009008754A - Anticuerpos novedosos contra igf-1r. - Google Patents

Anticuerpos novedosos contra igf-1r.

Info

Publication number
MX2009008754A
MX2009008754A MX2009008754A MX2009008754A MX2009008754A MX 2009008754 A MX2009008754 A MX 2009008754A MX 2009008754 A MX2009008754 A MX 2009008754A MX 2009008754 A MX2009008754 A MX 2009008754A MX 2009008754 A MX2009008754 A MX 2009008754A
Authority
MX
Mexico
Prior art keywords
antibodies against
novel antibodies
against igf
antibodies
antigen binding
Prior art date
Application number
MX2009008754A
Other languages
English (en)
Inventor
Paul Andrew Hamblin
Jonathan Henry Ellis
Alan Peter Lewis
Michael Neil Burden
Radha Shah
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0702888.9A external-priority patent/GB0702888D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2009008754A publication Critical patent/MX2009008754A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Abstract

La presente invención describe fragmentos de enlace de anticuerpos o de antígeno de los mismos, que se enlazan de forma específica a IGF-1R, específicamente h1GF-1 R. También son descritas preparaciones de anticuerpo que contienen fragmentos de enlace de anticuerpos o de antígenos de la presente invención. Los métodos para la producción de dichos fragmentos de enlace de anticuerpos o de antígeno y usos de los mismos, también son incluidos dentro del alcance de la presente invención.
MX2009008754A 2007-02-14 2008-02-12 Anticuerpos novedosos contra igf-1r. MX2009008754A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0702888.9A GB0702888D0 (en) 2007-02-14 2007-02-14 Novel Antibodies
US95321007P 2007-08-01 2007-08-01
PCT/EP2008/051655 WO2008098917A2 (en) 2007-02-14 2008-02-12 Novel antibodies against igf-ir

Publications (1)

Publication Number Publication Date
MX2009008754A true MX2009008754A (es) 2009-11-02

Family

ID=42025950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008754A MX2009008754A (es) 2007-02-14 2008-02-12 Anticuerpos novedosos contra igf-1r.

Country Status (5)

Country Link
JP (1) JP2010518140A (es)
KR (1) KR20090114449A (es)
EA (1) EA200900991A1 (es)
MX (1) MX2009008754A (es)
PE (1) PE20090107A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5972176B2 (ja) 2010-02-23 2016-08-17 サノフイ 抗アルファ２インテグリン抗体及びそれらの使用
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
CA2858389A1 (en) * 2011-12-15 2013-06-20 The Royal Institution For The Advancement Of Learning/Mcgill University Soluble igf receptor fc fusion proteins and uses thereof
CA3002741A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032028A1 (es) * 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005058967A2 (en) * 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications

Also Published As

Publication number Publication date
PE20090107A1 (es) 2009-03-20
KR20090114449A (ko) 2009-11-03
JP2010518140A (ja) 2010-05-27
EA200900991A1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
WO2008098917A3 (en) Novel antibodies against igf-ir
MX2010001237A (es) Nuevos anticuerpos.
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
PH12015501848A1 (en) Binding agents
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
UA92505C2 (ru) Композиции на основе антитела против cd3
MY174493A (en) Binding agents
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
AU2009260320A8 (en) Antibodies to IL-6 and their uses
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MY194997A (en) Anti-ccr7 antibody drug conjugates
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
WO2012027721A3 (en) Antibodies to matrix metalloproteinase 9
TW200510459A (en) RG1 antibodies and uses thereof
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
WO2011004028A3 (en) Tlr3 binding agents
MX2022000325A (es) Anticuerpos dirigidos contra dll3 y usos de los mismos.
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody